Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
August 6, 2018

Nicox starts Phase ll trial of NCX 470 against latanoprost 0.005%

Nicox has commenced a Phase ll clinical trial to examine the efficacy and safety of NCX 470 in comparison with latanoprost 0.005% for the treatment of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Nicox has commenced a Phase ll clinical trial to examine the efficacy and safety of NCX 470 in comparison with latanoprost 0.005% for the treatment of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

The multi-centre, double-masked, 28-day, parallel group dose-ranging trial has already enrolled ten patients.

During the trial, 420 patients are expected to randomise in various clinical sites across the US.

The trial’s primary endpoint is the mean reduction in diurnal IOP after four weeks of treatment, and its overall objective is to identify the appropriate dose of NCX 470 for Phase lll studies of the drug.

Top-line results from the trial are scheduled to be available by the second half of next year.

“We believe that NCX 470 may provide a clinically meaningful improvement over the current standard of care, and become a first-line therapy for these patients.”

Nicox chairman and CEO Michele Garufi said: “Based on our preclinical data, we believe that NCX 470 may provide a clinically meaningful improvement over the current standard of care, and become a first-line therapy for these patients.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

“The development of NCX 470 is testimony to the power of our efforts fuelled by the seamless collaboration between our US and European R&D teams, and follows on the back of the Food and Drug Administration (FDA) approval of our first-generation NO-donating compound VYZULTA, commercialised in the US since last December by our partner Bausch + Lomb.”

NCX 470 is a novel chemical entity developed as an ophthalmic solution of the new, second-generation nitric oxide (NO)-donating prostaglandin analogue for reducing IOP in patients with open-angle glaucoma and ocular hypertension.

Glaucoma is a group of ocular diseases which damages the optic nerve, thereby leading to peripheral and, ultimately, central visual field loss.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU